Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfgang Strube

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 19, 2022
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trialWolfgang Strube, Aslihan Aksar, Ingrid Bauer, et al.
The Lancet. Psychiatry|August 7, 2025
Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in GermanyChristian Plewnia, Bettina Brendel, Tobias Schwippel, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Pharmacopsychiatry|July 28, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric TrialElias Wagner, Wolfgang Strube, Thomas Görlitz, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
Brain, Behavior, and Immunity|April 12, 2024
Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders - An individual patient data meta-analysisMattia Campana, Vladislav Yakimov, Joanna Moussiopoulou, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 19, 2022
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trialWolfgang Strube, Aslihan Aksar, Ingrid Bauer, et al.
The Lancet. Psychiatry|August 7, 2025
Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in GermanyChristian Plewnia, Bettina Brendel, Tobias Schwippel, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Pharmacopsychiatry|July 28, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric TrialElias Wagner, Wolfgang Strube, Thomas Görlitz, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
Brain, Behavior, and Immunity|April 12, 2024
Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders - An individual patient data meta-analysisMattia Campana, Vladislav Yakimov, Joanna Moussiopoulou, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
Pageof 7